
Genesys Biolabs is focused on early detection of lung cancer through PAULA's Test, an affordable blood test that identifies lung cancer risk at the earliest stages. The test combines multiple tumor biomarker blood tests with personal health data using a machine learning algorithm to generate an accurate lung cancer risk profile. It targets high-risk individuals, especially current or former smokers, and aims to improve early diagnosis rates where traditional CT screening is limited. The test has been validated in independent studies showing 75% sensitivity and 80% specificity, offering a non-invasive, accessible screening alternative to improve lung cancer survival outcomes.

Genesys Biolabs is focused on early detection of lung cancer through PAULA's Test, an affordable blood test that identifies lung cancer risk at the earliest stages. The test combines multiple tumor biomarker blood tests with personal health data using a machine learning algorithm to generate an accurate lung cancer risk profile. It targets high-risk individuals, especially current or former smokers, and aims to improve early diagnosis rates where traditional CT screening is limited. The test has been validated in independent studies showing 75% sensitivity and 80% specificity, offering a non-invasive, accessible screening alternative to improve lung cancer survival outcomes.